Back to News
Market Impact: 0.2
Allogene's Executive VP & CFO Geoffrey Parker To Retire
Source: Nasdaq
Company FundamentalsManagement & Governance
Allogene Therapeutics announced the retirement of Geoffrey Parker, its Executive Vice President and CFO, effective November 6, 2026. The change is primarily governance/management-focused and is mildly negative, with potential uncertainty around future financial leadership and continuity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.15
Ticker Sentiment
ALLO-0.15
More News
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Indonesia’s Danantara pledges $5 billion to home-grown companies as MSCI once again threatens a downgrade
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- What Is an AI Research Agent?
- Bitcoin's 52% Crash Proves It's a Tech Stock: Here's What That Means for Portfolio Construction